HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ZBH
Zimmer Biomet Holdings, Inc.
ZBH's fundamentals are mixed: it turned 19% of its revenue into free cash flow, but its operating margin fell 3 points to 14%. At 26x earnings, it's trading below its usual 31x. Analysts expect earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ZBH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Under pressure |
ZBH's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ZBH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $105 | — |
| Cheap | 22x | $87.95 | -16% |
| Current | 26x | $105 | — |
| Fair | 31x | $123 | +18% |
| Expensive | 94x | $371 | +255% |
Historical ranges are pointers, not guarantees.
ZBH's PE is in its fair range at 26x. If earnings grow as analysts expect, today's price would be 12x next year's earnings, in its cheap range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ZBH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Moderate | |
| High |
Analysts expect ZBH's earnings to grow and its profitability to improve, with its revenue holding steady.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ZBH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.82 | +123% |
| Q3 2026 | $3.96 | -1.5% |
| Q2 2026 | $4.12 | +0.7% |
| Q1 2026 | $3.86 | -14% |
| Q4 2025 | $3.55 | -20% |
| Q3 2025 | $4.02 | -23% |
| Q2 2025 | $4.09 | -15% |
| Q1 2025 | $4.50 | -2.4% |
| Q4 2024 | $4.43 | -9.2% |
ZBH has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ZBH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ZBH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.1B | +3.1% |
| Q2 2026 | $2.2B | +4.8% |
| Q1 2026 | $2.1B | +9.3% |
| Q4 2025 | $2.2B | +11% |
| Q3 2025 | $2B | +9.7% |
| Q2 2025 | $2.1B | +7% |
| Q1 2025 | $1.9B | +1.1% |
| Q4 2024 | $2B | +4.3% |
ZBH's revenue has grown year over year for 15 quarters in a row: $2.1B last quarter, up 3.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | -2.6 points |
| Q2 2026 | 15% | +0.5 points |
| Q1 2026 | 18% | +2.6 points |
| Q4 2025 | 6.9% | -12 points |
| Q3 2025 | 18% | +2.2 points |
| Q2 2025 | 14% | -3.7 points |
| Q1 2025 | 15% | +1.2 points |
| Q4 2024 | 19% | +1 points |
ZBH has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ZBH on cash flow, with more consistent year-over-year improvement.
ZBH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $484.2M | +33% |
| Q2 2026 | $393.6M | +20% |
| Q1 2026 | $323.1M | -4.5% |
| Q4 2025 | $442.6M | -2.7% |
| Q3 2025 | $363.7M | +3.6% |
| Q2 2025 | $328.1M | +3.6% |
| Q1 2025 | $338.2M | +96% |
| Q4 2024 | $454.8M | -13% |
ZBH generated $1.6B in free cash flow over the past year, up 11% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ZBH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ZBH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -1.4M shares |
| 1 year | -3.7% | -7.4M shares |
| 3 years | -8.9% | -18.6M shares |
| 5 years | -12% | -25.5M shares |
| Available history | -10% | -21.5M shares |
ZBH has 191M diluted shares, down 3.7% from a year ago, with $829M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $78.5M |
| Q2 2026 | $250.7M |
| Q1 2026 | $250.1M |
| Q4 2025 | $250M |
| Q3 2025 | — |
| Q2 2025 | $7.2M |
| Q1 2025 | $229.8M |
| Q4 2024 | $72.2M |
ZBH spent $829M buying back its own shares over the past year, up 168% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ZBH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.1x | Elevated |
| Q2 2026 | 3.1x | Elevated |
| Q1 2026 | 3.1x | Elevated |
| Q4 2025 | 3.2x | Elevated |
| Q3 2025 | 2.8x | Moderate |
| Q2 2025 | 3.1x | Elevated |
| Q1 2025 | 2.5x | Moderate |
| Q4 2024 | 2.5x | Moderate |
ZBH's net debt is about 3.1 years of its operating earnings (EBITDA), up from 2.8 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ZBH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.1 | Neutral |
| Stochastic | 62.8 | Neutral |
ZBH's weekly RSI is 61 (neutral) and its Stochastic is 63 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ZBH PE vs Healthcare Sector
| Metric | ZBH | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 26x | 2.1% above |
| PE % | 45 | 29 | 16 pts above |
ZBH is trading at 26x earnings, in line with the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ZBH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $95.8 | 9.1% above |
| 20 week MA | $95.4 | 9.6% above |
| 50 week MA | $92.2 | 13% above |
| 100 week MA | $96.3 | 8.6% above |
| 200 week MA | $108.2 | 3.4% below |
ZBH has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
ZBH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $145.5 | $144.8 | -0.5% |
| 2021 | $144.8 | $123.2 | -15% |
| 2022 | $123.2 | $126.7 | +2.8% |
| 2023 | $126.7 | $121.7 | -3.9% |
| 2024 | $121.7 | $106.9 | -12% |
| 2025 | $106.9 | $90.8 | -15% |
| 2026 YTD | $90.8 | $104.6 | +15% |
ZBH has the edge over HIMS on returns for 2026, with the stronger performance.